Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dilution, licensing and petlife all discussed in the CC; Link and time marks below
** Petlife specifically is discussed at the beginning of the 3:40 extra continuation of Cc segment that airs immediately after the first segment of the CC - you can find this portion of the CC by simply fast forward to the end of first almost hour long segment and you’ll get to the last 3:40 continuation segment… petlife involvement explained and licensing is further discussed as well
~~~~~~~~~~~~~~~
41:25 Dilution discussed ** last stage of closing with investors attorney to “avoid future dilution” ***
42:00 investor engaging with FDA LOBBYIST to help FDA process
** investor has experience w distribution of Covid 19 vaccines
42:43 FDA status - discussed “second potential investor” - help to move application from pre Ind to Ind status
~~~~~~~~~~
O:00 petlife (ie at the beginning of 3:40 segment)
1:14 licensing question answer of 3:40 segments)
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Meeting link AND passcode to watch -
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
Exactly! QNTA Escozine AELIA MedolifeRx
https://www.sec.gov/Archives/edgar/data/1691430/000149315222011986/ex99-1.htm
Dr Mikaelian expresses at minute mark t56:25 this is his “life’s work”
…. in the CC many things are explained and answered along with current meetings and actions discussed / defined etc
GLTA. …
here’s to 2022 being a great year
Here’s the link once again below along with access passcode
56:25 “life’s work”
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
products, scorpions & patents - all real
https://medoliferx.com/science/
full US PATENT in 2012: (#US 8,097,284 B2)
https://aeliastore.com/
https://medoliferx.com/shop/drops/escozine-immunapen-original-drops/
GLTA QNTA MedolifeRx AELIA escozine
Shared CEO position already in the works and was discussed in the CC at the time mark 53:57 “Shared CEO” {position defined - active negotiations for CEO position, third round of interviews completed - CANDIDATE has extensive biotech experience & EXPERIENCE in taking Otc company(s) to NASDAQ
- roles of co-ceo positions discussed}
Link below To listen in and hear the segment about the shared ceo position and divided duties at
Cc link and code link below;
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
Here’s a breakdown of topics from the CC for reference…. Many questions were being raised online and through email / phone calls direct to MedolifeRx. The CC was in large part held to address directly the questions … also a lot of information was presented regarding science and more. Here’s my list from the cc … I’m sure I missed something, but it’s a quick guide to find answers
key topics that were discussed
4:45 start time
6:20 begin investors Q&A
7:00 SEC discussed
7:31 Auditor change / 8k item 4.01 discussed
813 OTC OTCQB discussed
8:56 Farmatsevtik Armenia
13:40 QNTA Main GOALS & PLANS
17:35 some Paxlovid users had symptoms relapse, versus with escozine symptoms did not return
18:35 PROVISIONAL PATENT now “ABLE TO SHARE PUBLICLY” escozine Covid 19 therapy “important goal”
20:22 CHART escozine therapy results EFFICACY charts
21:36 patient LUNG X-ray showing ASTOUNDING RESULTS from MONOTHERAPY escozine
22:54 Chief Scientific Officer Dr Matalka breaks down escozine ** lots of very good informative easy to follow slides - science of escozine explained very well *** worth listening / watching this portion, great visuals and easy to understand science of how Escozine works against Covid
26:36 *** [ “polarization of escozine significantly increased cox-2 inhibition in comparison with non polarized venom”]***<<
31:38 slide shown Escozine BLOCKS omicron
32:50 “beauty of Escozine”
33:30 explains COVID registration PROCESS versus CANCER Registration process
35:05 delay in Dominican Republic studies explained (** worth noting, ANY medical trial is at the mercy of available subjects that fit in a specified sub group etc .. Covid rates WERE down … NOW going back UP )
36:37 currently Mexico has ENOUGH patients for DOUBLE BLIND study
37:13 Mexico EXPORT certificate (explains easier to import from US to Mexico .. double blind test mentioned again)
38:06 *** FDA strategy summarized
“Actively working to completely FDA process”
*** Funding discussed to finished indoor facility in DR
41:25 Dilution discussed ** last stage of closing with investors attorney to “avoid future dilution” ***
42:00 investor engaging with FDA LOBBYIST to help FDA process
** investor has experience w distribution of Covid 19 vaccines
42:43 FDA status - discussed “second potential investor” - help to move application from pre Ind to Ind status
43:08 a vision for DISTRIBUTION and New Opportunities
46:25 WALGREENS dialogue .. speaker has “experience in retail space for 30 years” … meeting with WALGREENS mentioned
49:28 Kevin Harrington (spelling??) Group REACHED out To QNTA expressing interest in Representing them - product samples to be shipped
50:00-51:54 *LICENSING discussed*
(noted / reminder in the CC big pharma moves slow / process takes time)
51:56 name & SYMBOL CHANGE addressed
52:45 VENDING MACHINE lease discussed - modern style with visual screens for product video (ability to have video screen on the machine itself is what I understood)
53:57 “Shared CEO” position defined - active negotiations for CEO position, third round of interviews completed - CANDIDATE has extensive biotech experience & EXPERIENCE in taking Otc company(s) to NASDAQ
- roles of co-ceo positions discussed
55:50 addressed the PRE IND # and shows slide with direct communication with FDA showing the validity of the pre Ind #
56:45 dispels myth of his salary
57:25 “life’s work” *** worth hearing this portion, imo, shows a testimony and drive of the culmination of research to where qnta is now and moving forward toward to a continued path to achieving goals
***
As always, one should do DD
Listen to the CC. Read the data etc
GLTA
***
Cc link and code link below;
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
Unfortunately last year stock woes are pretty brutal .. the RS debacle … then the fda adding more tests requirements after Covid vaccines came in the market now all drugs must show how they affect the human body on a dna level … the sec thing … creating a downward spiral …
Licensing doesn’t happen over night - negotiations etc take an inordinate amount of time … this was discussed on the last cc in regards to https://www.yet2.com/
My personal opinion is once the sec situation is cleared then we see the price jump again … in the meantime I’m still using the immunipen daily and feel great
The current sp while extremely cringeworthy to look at … will hopefully be back up soon.
Fda related things take time …
https://www.fda.gov/drugs/special-features/frequently-asked-questions-about-fda-drug-approval-process#4
50:00-51:54 *LICENSING discussed*
(noted / reminder in the CC big pharma moves slow / process takes time)
Listen here starting at the 50:00 minute mark to hear about licensing
Yet2 is mentioned in regards to licensing
https://www.yet2.com/
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
It’s reasonable if it’s July …
Here’s why
It has been said, with heartfelt tone, that it is explainable what’s going on … and they are working with the sec to get things concluded in a timely manner …
Unfortunately, the sec isn’t a private company so they don’t have as much sense of urgency to conclude things as the individuals being investigated…
If mid / end of July is projected I say fantastic!!! As if could’ve been a ten year drag … in the meantime QNTA is doing well to keep moving forward with getting goals in line to be accomplished
Here’s a quick read on sec investigations
https://www.seclaw.com/long-sec-investigation-take/
QNTA MedolifeRx E$COZINE AELIA
That sounds reasonable, thanks for sharing :)
QNTA MedolifeRx AELIA E$COZINE
…..
If one applies this thinking … July completion time frame makes a lot of sense [{“Audits are typically scheduled for three months from beginning to end, which includes four weeks of planning, four weeks of fieldwork and four weeks of compiling the audit report. The auditors are generally working on multiple projects in addition to your audit. The auditors' time will be divided among all of their projects, with some weeks heavily focused on your audit and other weeks less focused on your audit.”}]
Answer follows below ;~)
Who is Frank Fosco? I asked …
… as he was introduced in the opening of the last CC … when I emailed MedolifeRx to find out what is role is with QNTA / MedolifeRx / AELIA … I was happy to open my email and read their reply
… also, for reference, I put Frank Fosco linkedin link below as well
… impressive imo
Listen / watch at
4:14-4:38 Frank Fosco is on the the call talking https://www.linkedin.com/in/frank-m-fosco-jr-02931095
(Note ** Frank Fosco is the CEO of Green Krystal Technologies **)
When i emailed MedolifeRx to ask;
“what is his role in QNTA?”
MedolifeRx replied thusly …
*****
[{ “Unfortunately, we did not have enough time to discuss the Immunapen distribution through Green Krystal Technologies, of which Frank Fosco is the CEO. That is already in motion and we hope to announce more regarding that soon!”}]
*******
I encourage folks to tune into the CC and hear the candid dialogue at the 4:14 mark where he is chatting with the other speaker about distributing and sales etc (I went to re listen to cc as I recalled his introduction but didn’t recall him speaking more than the opening)… during this clip of time the meeting hadn’t officially started as they were waiting for folks to get on the zoom call …. Like I’ve mapped out, there’s a LOT of information that was packed into that CC and lots of preverbal irons in the fire so to speak .. both “big pharma” and anything connected to waiting for “fda” or governments TAKES TIME …
Side note ** I’ve used the immunipen myself for months now - works as advertised! … I’ve also dug deep into the science behind scorpion venom peptides etc … the research in this area of study continues to be gaining ground, and has remarkable seemingly endless possibilities/ potential of use… but like all things medicine related it takes time …and money… to move it forward … Also equally if not more important than a great product or idea is getting the message / product seen by the right people …. I was impressed with Frank Fosco bio and he clearly has been in this space for quite awhile …
Here’s to PAYTIENCE Paying off once things culminate as hoped
E$COZINE QNTA MedolifeRx AELIA
https://medoliferx.com/shop/drops/escozine-immunapen-original-drops/
….good question …
Hopefully not to long … might be worth reaching out and asking?? But ultimately I wouldn’t think it would take too long?
In the meantime I received this month’s immunipen supply in the mail - the viscosity formula has been changed which is FANTASTIC!!! I cannot say it enough - if your invested and have not yet tried the products I highly recommend them - they work as described:)
https://medoliferx.com/shop/drops/escozine-immunapen-original-drops/
The products REALLY Do Speak for themselves!! I’ve been using the imunapen for 8 months now and works as described!
The muscle rub makes for a great gift :) for anyone in your life who is even remotely active - my elderly parents really like how well it works - and as a great bonus the scent of the product is great too
https://medoliferx.com/shop/drops/escozine-immunapen-original-drops/
The muscle rub is awesome and works as advertised as well
https://aeliastore.com/
https://ir.quantrx.com/
Thus far I’ve had all my questions answered either directly via email, through phone conversation, and the conference calls. They have been very transparent imo as to what’s going on - happy to have dialogue when called upon … in regards to otc it was explicitly said in the conference call when they go through auditing process with the new auditor this is a potential situation that could arise and will be “temporary” during auditing … which all makes sense …
In the mean time here’s the link for easy reference
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
Listen to the CC at this time portion for explanation:
7:31 Auditor change / 8k item 4.01 discussed
813 OTC OTCQB discussed
this is temporary AND WAS DISCUSSED in the last CC at the 8:35 minute mark. I’ll paste link to recording for reference .. specifically noted this may occur temporarily… and is explained .. click on link provide your email etc then use the passcode provided below to be able to watch the recording … you can fast forward to the time to if only wanting to hear a snippet at a time
At 8:35 “temporary”
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
Listen to the CC at this time portion for explanation:
7:31 Auditor change / 8k item 4.01 discussed
813 OTC OTCQB discussed
Here’s some other key time stops to get clarity for frequently asked questions :
4:45 start time
6:20 begin investors Q&A
7:00 SEC discussed
7:31 Auditor change / 8k item 4.01 discussed
813 OTC OTCQB discussed
8:56 Farmatsevtik Armenia
13:40 QNTA Main GOALS & PLANS
17:35 paxlovid relapse unlike escozine symptoms did not return
18:35 PROVISIONAL PATENT now “ABLE TO SHARE PUBLICLY” escozine Covid 19 therapy “important goal”
20:22 CHART escozine therapy results EFFICACY charts
21:36 patient lung exray showing ASTOUNDING RESULTS from MONOTHERAPY escozine
22:54 Chief Scientific Officer Dr Matalka breaks down escozine (lots of very good information easy to follow slides - science of escozine explained very well *** worth listening / watching this portion, great visuals and easy to understand science of how Escozine works against Covid
26:36 *** [ “polarization of escozine significantly increased cox-2 inhibition in comparison with non polarized venom”]
31:38 slide shown Escozine BLOCKS omicron
32:50 “beauty of Escozine”
33:30 COVID registration PROCESS versus CANCER Registration process
35:05 delay in Dominican Republic studies explained (** worth noting, ANY medical trial is at the mercy of available subjects that fit in a specified sub group etc .. Covid rates WERE down … NOW going back UP )
36:37 currently Mexico has ENOUGH patients for DOUBLE BLIND study
37:13 Mexico EXPORT certificate (explains easier to import from US to Mexico .. double blind test mentioned again)
38:06 FDA strategy summarized
“Actively working to completely FDA process”
Funding discussed to finished indoor facility in DR
41:25 Dilution discussed ** last stage of closing with investors attorney to “avoid future dilution” ***
42:00 investor engaging with FDA LOBBYIST to help FDA process
** investor has experience w distribution of Covid 19 vaccines
42:43 FDA status - discussed “second potential investor” - help to move application from pre Ind to Ind status
43:08 a vision for DISTRIBUTION and New Opportunities
46:25 WALGREENS dialogue .. speaker has “experience in retail space for 30 years” … meeting with WALGREENS mentioned
49:28 Kevin Harrington (spelling??) Group REACHED out To QNTA expressing interest in Representing them - product samples to be shipped
50:00-51:54 *LICENSING discussed*
(noted / reminder in the CC big pharma moves slow / process takes time)
51:56 name & SYMBOL CHANGE addressed
52:45 VENDING MACHINE lease discussed - modern style with visual screens for product video (ability to have video screen on the machine itself is what I understood)
53:57 Shared CEO position defined
Activitie negotiations for CEO position, third round of interviews completed - CANDIDATE has extensive biotech experience & EXPERIENCE in taking Otc company to NASDAQ
roles of co ceo positions discussed
55:50 addressed the PRE IND # and shows slide with direct communication with FDA showing the validity of the pre Ind #
56:45 dispels myth of his salary
57:25 “life’s work” *** worth hearing this portion, imo, shows a testimony and drive of the culmination research to where qnta is now and moving forward on a continued path in a achieving goals
***
As always, one should do DD
Listen to the CC. Read the data etc
GLTA
***
Cc link and code link below;
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
this is temporary AND WAS DISCUSSED in the last CC at the 8:35 minute mark. I’ll paste link to recording for reference .. specifically noted this may occur temporarily… and is explained .. click on link provide your email etc then use the passcode provided below to be able to watch the recording … you can fast forward to the time to if only wanting to hear a snippet at a time
At 8:35 “temporary”
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
Listen to the CC at this time portion for explanation:
7:31 Auditor change / 8k item 4.01 discussed
813 OTC OTCQB discussed
Here’s some other key time stops to get clarity for frequently asked questions :
4:45 start time
6:20 begin investors Q&A
7:00 SEC discussed
7:31 Auditor change / 8k item 4.01 discussed
813 OTC OTCQB discussed
8:56 Farmatsevtik Armenia
13:40 QNTA Main GOALS & PLANS
17:35 paxlovid relapse unlike escozine symptoms did not return
18:35 PROVISIONAL PATENT now “ABLE TO SHARE PUBLICLY” escozine Covid 19 therapy “important goal”
20:22 CHART escozine therapy results EFFICACY charts
21:36 patient lung exray showing ASTOUNDING RESULTS from MONOTHERAPY escozine
22:54 Chief Scientific Officer Dr Matalka breaks down escozine (lots of very good information easy to follow slides - science of escozine explained very well *** worth listening / watching this portion, great visuals and easy to understand science of how Escozine works against Covid
26:36 *** [ “polarization of escozine significantly increased cox-2 inhibition in comparison with non polarized venom”]
31:38 slide shown Escozine BLOCKS omicron
32:50 “beauty of Escozine”
33:30 COVID registration PROCESS versus CANCER Registration process
35:05 delay in Dominican Republic studies explained (** worth noting, ANY medical trial is at the mercy of available subjects that fit in a specified sub group etc .. Covid rates WERE down … NOW going back UP )
36:37 currently Mexico has ENOUGH patients for DOUBLE BLIND study
37:13 Mexico EXPORT certificate (explains easier to import from US to Mexico .. double blind test mentioned again)
38:06 FDA strategy summarized
“Actively working to completely FDA process”
Funding discussed to finished indoor facility in DR
41:25 Dilution discussed ** last stage of closing with investors attorney to “avoid future dilution” ***
42:00 investor engaging with FDA LOBBYIST to help FDA process
** investor has experience w distribution of Covid 19 vaccines
42:43 FDA status - discussed “second potential investor” - help to move application from pre Ind to Ind status
43:08 a vision for DISTRIBUTION and New Opportunities
46:25 WALGREENS dialogue .. speaker has “experience in retail space for 30 years” … meeting with WALGREENS mentioned
49:28 Kevin Harrington (spelling??) Group REACHED out To QNTA expressing interest in Representing them - product samples to be shipped
50:00-51:54 *LICENSING discussed*
(noted / reminder in the CC big pharma moves slow / process takes time)
51:56 name & SYMBOL CHANGE addressed
52:45 VENDING MACHINE lease discussed - modern style with visual screens for product video (ability to have video screen on the machine itself is what I understood)
53:57 Shared CEO position defined
Activitie negotiations for CEO position, third round of interviews completed - CANDIDATE has extensive biotech experience & EXPERIENCE in taking Otc company to NASDAQ
roles of co ceo positions discussed
55:50 addressed the PRE IND # and shows slide with direct communication with FDA showing the validity of the pre Ind #
56:45 dispels myth of his salary
57:25 “life’s work” *** worth hearing this portion, imo, shows a testimony and drive of the culmination research to where qnta is now and moving forward on a continued path in a achieving goals
***
As always, one should do DD
Listen to the CC. Read the data etc
GLTA
***
Cc link and code link below;
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
“COVID-19 cases rising in the U.S. heading into summer”
That’s Great news!
Here’s the products and retail pages the infomercial folks gave the positive review for below …. If as an investor or one looking to invest - try the products if you haven’t already - they definitely work as described for my family … both imunapen and muscle rub work great!!
Immunipen:
https://medoliferx.com/shop/drops/escozine-immunapen-original-drops/
Muscle rub and other products:
https://aeliastore.com/
https://www.beckershospitalreview.com/public-health/covid-19-cases-tick-up-in-9-states.html
I use the escozine immunipen daily - as an investor I wanted to try the product - glad I did - works as described!!
https://medoliferx.com/shop/drops/escozine-immunapen-original-drops/
At 20 minute mark explains how escozine is effective against Covid
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
20:22 CHART escozine therapy results EFFICACY charts
21:36 patient LUNG X-ray showing ASTOUNDING RESULTS from MONOTHERAPY escozine
22:54 Chief Scientific Officer Dr Matalka breaks down escozine ** lots of very good informative easy to follow slides - science of escozine explained very well *** worth listening / watching this portion, great visuals and easy to understand science of how Escozine works against Covid
26:36 *** [ “polarization of escozine significantly increased cox-2 inhibition in comparison with non polarized venom”]***<<
31:38 slide shown Escozine BLOCKS omicron
32:50 “beauty of Escozine”
I concur with your statement ; “QNTA has many things going for it. It is speculative, however if the cards fall as planned, investors will be rewarded handsomely.”
Fun fact, MedilifeRx Nagoya Protocol with the Dominican Republic https://unctad.org/system/files/non-official-document/ditc-ted-06042022-Oceans4-Silvander.pdf
Licensing discussed : MedilifeRx was contacted by with interest in polarization technology by Yet2,
their website is
https://www.yet2.com/
Listen on the CC at
50:00-51:54 *LICENSING discussed*
(noted / reminder in the CC big pharma moves slow / process takes time)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
BlazingStocks, Your most welcome!!!
https://medoliferx.com/shop/drops/escozine-immunapen-original-drops/
?? ??
https://aeliastore.com/shop/
In the conference call at time mark 46:25 WALGREENS was talked about
.. the person speaking has “experience in retail space for 30 years” … said meeting with WALGREENS
They discussed a trial launch likely on the east coast … I’d suggest listen to cc at that time mark .. then send follow up questions about the Walgreens mention to the following …
ir@medoliferx.com
I can only relay what I also heard over the CC … plan is as I gather try a few products in as many as 400 stores (? I can’t recall all the dialogue that is why I mapped out the cc with key words to be able to go back and listen )
On a side note I do use the immunipen myself now for 7 months … the product works as described
… yes, the Conference did indeed happen, yes folks were tuned in … if one wants to listen about the otc
Here’s where the OTC situation is explained (8:13 minute mark)
As always, it’s good to listen in for oneself … link to cc below
7:31 Auditor change / 8k item 4.01 discussed
8:13 OTC OTCQB discussed
As always, one should do DD
Listen to the CC. Read the data etc
GLTA
***
Cc link and code link below;
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
Your welcome… here’s more key topics that were discussed
4:45 start time
6:20 begin investors Q&A
7:00 SEC discussed
7:31 Auditor change / 8k item 4.01 discussed
813 OTC OTCQB discussed
8:56 Farmatsevtik Armenia
13:40 QNTA Main GOALS & PLANS
17:35 some Paxlovid users had symptoms relapse, versus with escozine symptoms did not return
18:35 PROVISIONAL PATENT now “ABLE TO SHARE PUBLICLY” escozine Covid 19 therapy “important goal”
20:22 CHART escozine therapy results EFFICACY charts
21:36 patient LUNG X-ray showing ASTOUNDING RESULTS from MONOTHERAPY escozine
22:54 Chief Scientific Officer Dr Matalka breaks down escozine ** lots of very good informative easy to follow slides - science of escozine explained very well *** worth listening / watching this portion, great visuals and easy to understand science of how Escozine works against Covid
26:36 *** [ “polarization of escozine significantly increased cox-2 inhibition in comparison with non polarized venom”]***<<
31:38 slide shown Escozine BLOCKS omicron
32:50 “beauty of Escozine”
33:30 explains COVID registration PROCESS versus CANCER Registration process
35:05 delay in Dominican Republic studies explained (** worth noting, ANY medical trial is at the mercy of available subjects that fit in a specified sub group etc .. Covid rates WERE down … NOW going back UP )
36:37 currently Mexico has ENOUGH patients for DOUBLE BLIND study
37:13 Mexico EXPORT certificate (explains easier to import from US to Mexico .. double blind test mentioned again)
38:06 *** FDA strategy summarized
“Actively working to completely FDA process”
*** Funding discussed to finished indoor facility in DR
41:25 Dilution discussed ** last stage of closing with investors attorney to “avoid future dilution” ***
42:00 investor engaging with FDA LOBBYIST to help FDA process
** investor has experience w distribution of Covid 19 vaccines
42:43 FDA status - discussed “second potential investor” - help to move application from pre Ind to Ind status
43:08 a vision for DISTRIBUTION and New Opportunities
46:25 WALGREENS dialogue .. speaker has “experience in retail space for 30 years” … meeting with WALGREENS mentioned
49:28 Kevin Harrington (spelling??) Group REACHED out To QNTA expressing interest in Representing them - product samples to be shipped
50:00-51:54 *LICENSING discussed*
(noted / reminder in the CC big pharma moves slow / process takes time)
51:56 name & SYMBOL CHANGE addressed
52:45 VENDING MACHINE lease discussed - modern style with visual screens for product video (ability to have video screen on the machine itself is what I understood)
53:57 “Shared CEO” position defined - active negotiations for CEO position, third round of interviews completed - CANDIDATE has extensive biotech experience & EXPERIENCE in taking Otc company(s) to NASDAQ
- roles of co-ceo positions discussed
55:50 addressed the PRE IND # and shows slide with direct communication with FDA showing the validity of the pre Ind #
56:45 dispels myth of his salary
57:25 “life’s work” *** worth hearing this portion, imo, shows a testimony and drive of the culmination of research to where qnta is now and moving forward toward to a continued path to achieving goals
***
As always, one should do DD
Listen to the CC. Read the data etc
GLTA
***
Cc link and code link below;
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
Thanks! .. and your welcome, glad you find it helpful. … I like to go back and relisten to CC’s, the break down makes it’s helpful when searching for scientific data slides for example etc
For example ..,at the 21:36 time mark is a photo of lung x-rays. I was looking for this particular thing to show some one …having the below mapped out it made for easy reference ….
** link to the CC at bottom of this post
4:45 start time
6:20 begin investors Q&A
7:00 SEC discussed
7:31 Auditor change / 8k item 4.01 discussed
813 OTC OTCQB discussed
8:56 Farmatsevtik Armenia
13:40 QNTA Main GOALS & PLANS
17:35 some Paxlovid users had symptoms relapse, versus with escozine symptoms did not return
18:35 PROVISIONAL PATENT now “ABLE TO SHARE PUBLICLY” escozine Covid 19 therapy “important goal”
20:22 CHART escozine therapy results EFFICACY charts
21:36 patient LUNG X-ray showing ASTOUNDING RESULTS from MONOTHERAPY escozine
22:54 Chief Scientific Officer Dr Matalka breaks down escozine ** lots of very good informative easy to follow slides - science of escozine explained very well *** worth listening / watching this portion, great visuals and easy to understand science of how Escozine works against Covid
26:36 *** [ “polarization of escozine significantly increased cox-2 inhibition in comparison with non polarized venom”]***<<
31:38 slide shown Escozine BLOCKS omicron
32:50 “beauty of Escozine”
33:30 explains COVID registration PROCESS versus CANCER Registration process
35:05 delay in Dominican Republic studies explained (** worth noting, ANY medical trial is at the mercy of available subjects that fit in a specified sub group etc .. Covid rates WERE down … NOW going back UP )
36:37 currently Mexico has ENOUGH patients for DOUBLE BLIND study
37:13 Mexico EXPORT certificate (explains easier to import from US to Mexico .. double blind test mentioned again)
38:06 *** FDA strategy summarized
“Actively working to completely FDA process”
*** Funding discussed to finished indoor facility in DR
41:25 Dilution discussed ** last stage of closing with investors attorney to “avoid future dilution” ***
42:00 investor engaging with FDA LOBBYIST to help FDA process
** investor has experience w distribution of Covid 19 vaccines
42:43 FDA status - discussed “second potential investor” - help to move application from pre Ind to Ind status
43:08 a vision for DISTRIBUTION and New Opportunities
46:25 WALGREENS dialogue .. speaker has “experience in retail space for 30 years” … meeting with WALGREENS mentioned
49:28 Kevin Harrington (spelling??) Group REACHED out To QNTA expressing interest in Representing them - product samples to be shipped
50:00-51:54 *LICENSING discussed*
(noted / reminder in the CC big pharma moves slow / process takes time)
51:56 name & SYMBOL CHANGE addressed
52:45 VENDING MACHINE lease discussed - modern style with visual screens for product video (ability to have video screen on the machine itself is what I understood)
53:57 “Shared CEO” position defined - active negotiations for CEO position, third round of interviews completed - CANDIDATE has extensive biotech experience & EXPERIENCE in taking Otc company(s) to NASDAQ
- roles of co-ceo positions discussed
55:50 addressed the PRE IND # and shows slide with direct communication with FDA showing the validity of the pre Ind #
56:45 dispels myth of his salary
57:25 “life’s work” *** worth hearing this portion, imo, shows a testimony and drive of the culmination of research to where qnta is now and moving forward toward to a continued path to achieving goals
***
As always, one should do DD
Listen to the CC. Read the data etc
GLTA
***
Cc link and code link below;
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
56:25 Dr Mikaelian expresses this is his life’s work … I plan on posting a pretty comprehensive Break down of what I found ti be key minute mark points in the latest CC. However … I’m going to finish drinking my coffee first ;) lol
… in the mean time, if invested in qnta, a customer or someone thinking to invest
Start with 56:25 “life’s work” …. I personally feel there is great potential exponentially for escozine and polarization technology… Dr Mikaelian research on escozine is over 17 years thus far … big pharma endeavors take an inordinate amount of time - however, when they do finally break out have potential as we all know to be huge … in the CC many things are explained and answered along with current meetings and actions defined etc
GLTA. … here’s the link …
Good morning everyone - here’s to 2022 being a great year
Here’s the link once again
56:25 “life’s work”
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
** Licensing discussed - Listen at the 50:00 minute mark (50:00 through 51:54)
Noteworthy, big pharma process Is slow and takes time HOWEVER this segment on the licensing talk is worth tuning into to head
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
Your most welcome.
Check out 31:38 where they discuss omicron .. Dr Matalka is showing slides discussing how escozine blocks omicron
Then .. 32:50 The beauty of the power of escozine..
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
Your welcome
I’m trying to take some notes from the CC with time stamps so I can let folks know where to tune I and listen for specific topics they are querying …. Lots to unpack in that cc …
GLTA
You’ll find dialogue in regards to your query starting at the 7:00 minute mark of the CC (for convenience I put the link to conference call and password to listen at the bottom of this post)
*** At 7:00 the sec is mentioned then
At the 7:31 mark in the CC auditor change discussed along with otcqb / otc pink / otcb …. 8k mentioned Item 4.01 discussed
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
recent CC minute mark discussing “avoiding future shareholder dilution” engaging FDA lobbyist, private investors, lab etc.
Listen at minute mark 41:25
Actively working with private investors re fda lobbyists
It’s worth listening to, and or relistening to
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
GLTA and as always Do your Own DD
Schoondale …. Asked “Which begs the question is family running FARMTEVSIK? Especially given the nepotism in Quanta itself. And why haven't revenues shown up in filings? “
They did show up in filings - I actually posted that information when this topic arose a few weeks ago … I’m out of the office but if you scroll back at posts you’ll see where it was noted
Schoondale also asked
“Care to get an answer to that? They never seem to answer or respond to significant issues.”
I’ve got many answers by emailing them and also many questions are answered in the CC (link once again posted for reference below)
These things have been answered in other replies / posts but here it is again …
In addition to this question above so many topics were addressed and answered - I shared a link to send in questions before the cc - which many folks did just that, submitted questions/ concerns etc which were answered on the cc. I’ll share the cc link here again now for reference;
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
Ultimately, the answer is No QNTA does NOT own that company in Armenia. The sale As talked about in the CC had issues because of the customs regulations surrounding the word homeopathic.. they deemed homeopathic in that country as a drug category which then held up the entire lot, as it was not being sold as a drug … Fast forward apparently the use of the word “supplement” is ok …
Anyways… the Armenian company is owned by a relative but the issue at hand had zero to do with it being family but rather a government customs issue … which again Was explained on the latest cc
Also I’ve posted on this thread where the initial sale was documented and filed …
I suggest listening to the cc
And or email MedolifeRx directly and ask
They have been transparent and most helpful in getting back to me when I’ve had questions… and the fact they have an open forum for questions to be discussed on their CC s speaks volumes… they truly do want investors to understand what’s happening in the company and things they are working toward …
For example Listen at Minute mark 19:00
“able to share publicly now” because they have filed for a provisional patent
GREAT escozine Covid therapy data
Key wording “able to share” … now that they have the provisional patent application That info can be shared…
There is a lot to hear on the cc. As an investor and as a customer I am personally excited for things in the works … here’s the link for those who missed
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
GLTA and as always Do your Own DD
Just because some posts in all caps doesn’t mean their postings have merrit
Ultimately, research, listen to the CC, reach out direct to the company, try the products for yourself… in doing those things is how I became invested …
I would not call this a flip… again GLTA
Here’s the company investor relations page for reference and contact information
https://ir.quantrx.com/
At time stamp 8:56 during the cc (link below) your question is answered
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
Again, as a shareholder, potential investor, current investor, potential customer or customer, it’s always good to do some DD
And hear / read the answers directly from the source
For reference, here’s a few start points of the Cc to help folks out … but, personally as an investor I’d suggest start at 4:19 mark with paper in hand and take notes - for example I was able to quickly note these minute marks just now and subsequently share to this lively discussion about Qnta :
4:19 minute mark the CC begins
6:20 minutes mark is where the Q&A from investors to qnta begins
8:56 the Armenian company question is addressed
19:00 “able to share publicly now” because they have filed for a provisional patent GREAT escozine Covid therapy data is shared
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
Your most welcome
I like this quote from the email .. it’s worth reposting… have a question? Ask :)
That’s what I did ;~)
[{ “We strive to be transparent and honest with the public, and continue to welcome any questions directed to ir@medoliferx.com. “}]
Flight info was NOT for Ceo
I simply emailed, asked… and received an answer. - See below ;
[{“As our shareholder, you have the right to know that the flight details that were shown during the latest investor conference call is NOT related to business matters and is NOT for the CEO. This flight was for the CEO’s wife and youngest child, who are visiting their family in Kyrgyzstan for personal matters. Because of that, the flight details were shared to the CEO’s calendar. Dr. Mikaelian is still working from our Burbank office in California, as mentioned during the conference call.
This is an important time for the company and our shareholders, and we are hard at work to complete the many projects in progress. We strive to be transparent and honest with the public, and continue to welcome any questions directed to ir@medoliferx.com. “}]
Listen at Minute mark 19:00
“able to share publicly now” because they have filed for a provisional patent
GREAT escozine Covid therapy data
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
Does any one know factually what the trip was for? Does anyone know factually it was company paid for that matter?
Ultimately, my point was “traveling” and or the fact a flight was looked at doesn’t mean much … people traverse the globe for all kinds of reasons - both personal and for business on a daily basis .. ultimately it’s not unusual for anyone to travel abroad anymore… if it were 1970 it might be more of an intriguing question but it’s 2022 - flying international isn’t a big deal.
I’d suggest it might be a good idea to reach and simply ask them - if it’s not qnta related they don’t owe an explanation… if it’s a related business meeting as discussed in the cc - as there were many various deals / connections being of spoke of - never did we learn what country the other parties of said deals reside .. hence my yawn… travel equals yawn … the cc was recorded for all to see the sec fda all of us .. basically anyone could tune in and watch or rewatch the link - no one is putting anything in plane sight they want hidden … it’s a small company with an great goal of bringing escozine to market via fda for cancer therapy/ treatments… cancer patients inadvertently cured their Covid while using escozine… hooray for MedolifeRx moving fwd in testing and moving ahead with learning more … Covid and cancer both have many mutations and unfortunately both are here to stay …
Escozine in many studies is proving to be great at effective toward many things ..
What we all know is any thing big pharma related takes an inordinate amount of time decades of research and lots of money ..
As for the dilution, obviously I don’t like it any more than anyone else .. however, it’s been explained … noteworthy in the CC they made it clear they were hoping not to dilute more going forward if / when they finish up the current private investor agreement (this was specifically on the latest CC) this private investment situation was going to help in getting the the indoor scorpion breeding facility construction completed without need to dilute for that construction …. Soooo maybe the flight was to solidify that?
The last CC was had in large part specifically to give answers to the plethora of questions on from investors from this forum and others to be able to submit questions / concerns and then they replied
I felt a great deal of questions were indeed addressed. A great deal of information was given in that CC. It’s worth relistening to .. or I’d suggest reach out directly with any additional questions/ concerns.
https://ir.quantrx.com/
“Two new Omicron variants are spreading. Will they drive a new U.S. surge?”
BYSANJAY MISHRA
PUBLISHED MAY 9, 2022
The subvariants BA.4 and BA.5 may dodge immunity, especially in unvaccinated people, possibly causing a spike in infections worldwide.
New versions of Omicron are again causing a surge of COVID-19 cases in South Africa, and studies show that these new subvariants are so different from the original version of Omicron that immunity generated from a previous infection may not provide much protection.
Dubbed BA.4 and BA.5, the new subvariants are nearly identical to each other, and both are more transmissible than the Omicron BA.2 subvariant. In South Africa, they replaced the BA.2 strain in less than a month. They are now responsible for a spike in South Africa’s COVID-19 cases, which have tripled since mid-April.
“If you were unvaccinated, what you got is almost no immunity to BA.4 and BA.5,” says Alex Sigal, a virologist at the Africa Health Research Institute and at the University of KwaZulu-Natal. “There might be some immunity that may be enough to protect against severe disease, but not sufficient to protect against symptomatic infection.”
South Africa is the worst hit country on the continent, with more than 100,523 official deaths from COVID-19—and that’s likely a gross underestimate according to a recent study in The Lancet. With BA.4 and BA.5 now on the rise, the death toll is likely to grow, as only a third of the South African population has received a COVID-19 vaccine; the rate of vaccination is even lower in the rest of Africa.
https://www.nationalgeographic.com/science/article/two-new-omicron-variants-are-spreading-will-they-drive-a-new-us-surge?rid=442B7C2013F1C1329C143BF2E7B9E8E3&cmpid=org=ngp::mc=crm-email::src=ngp::cmp=editorial::add=Health_20220516_Audience_Correction
If you haven’t yet tried the imunapen… I recommend it :) with Covid on the rise it’s a helpful tool in keeping your immune system boosted
https://medoliferx.com/shop/drops/escozine-immunapen-original-drops/
MedolifeRx AELIA escozine QNTA
GLTA
Yawn … a ceo is traveling .. people do that all the time .. was it for business perhaps? In the conference call there was discussion of various deals in the works
Was the travel personal? Who knows
Not sure why “reading a script” is anything but GOOD … MANY questions were asked of them AND many floated conspiracies have been hurled again them so it stands to reason they would READ the answers as to ensure the questions were answered …
Late filing… yawn again…. Sure they’ve filled paper work late in the past HOWEVER it’s always been filed within confines of rules of extension
What we know is he said there were talks with investors that would ideally stop the need for dilution that are in the works now THIS would then fund the completion of the indoor scorpion breeding facility
Imo I suggest folks do there own DD and listen to the latest conference call and not rely on others opinions of data or speculation
GLTA
Link below to CC
fyi Access passcode at bottom of text
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r